Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

Summary

A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the epidermal growth factor receptor (EGFR) inhibitor, Cetuximab in patients with metastatic colorectal cancer (mCRC) harboring Adenomatous polyposis coli (APC), tumor protein p53 (TP53) and RAS mutations.

Timeline

Start

2021-11-03

Primary completion

2024-02-20

Completion

2024-05-03

Outcome

Outcome not reported

Stopped (Enrollment): “PI Determination - Slow recruitment, funding concerns, poor response to treatment”

Drugs

Indications